drugset / Trial / NCT00786669
A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to test the safety and of adding bevacizumab to the established regimen of vincristine, oral irinotecan, and temozolomide (VOIT) and see what effects it has in pediatric patients with relapsed or refractory solid tumors.
Timeline
- Start
- 2008-10
- Primary completion
- 2012-11
- Completion
- 2012-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Background | Cefixime | Other / unclassified | 8 mg/kg | — |
| Background | Cefpodoxime | Small molecule | 5 mg/kg | — |
| Background | Irinotecan | Small molecule | 90 mg/m2 | Oral |
| Background | Temozolomide | Small molecule | 3.3 mg/kg | Oral |
| Background | Temozolomide | Small molecule | 100 mg/m2 | Oral |
| Background | Vincristine | Small molecule | 0.05 mg/kg | Intravenous |
| Background | Vincristine | Small molecule | 1.5 mg/m2 | Intravenous |